Experimental lung cancer vaccine trial halted early
NCT ID NCT04432207
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested an experimental immunotherapy called IMU-201 (PD1-Vaxx) in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or combined with another immunotherapy drug (atezolizumab) and sometimes chemotherapy. The goal was to check safety and find the right dose. However, the study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMU-201 (PD1-Vaxx), a vaccine-like immunotherapy that trains the immune system to target PD-1
What this could lead to
If it works, this could offer a new way to control advanced lung cancer by helping the immune system attack cancer cells.
What could go wrong
This was a very early (Phase 1) trial that was terminated, so results are limited. The approach is still experimental and may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cabrini Malvern Hospital
Melbourne, Victoria, 3000, Australia
-
Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Macquarie University
Macquarie, New South Wales, 2109, Australia
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Ohio State University Medical Center
Columbus, Ohio, 43210, United States